Next Generation Botanical Drugs for Complex Diseases
Canurta Therapeutics develops multi-target botanical therapies with AI-backed discovery and modeling to change how we treat inflammation and neurological diseases.
Our PolyKye™ platform rapidly identifies novel bioactives to guide compound selection, disease pathways targeting, and advanced formulation.
Unlocking the Potential of Multi-Target Therapies
Our research into bioactive compounds reveals their ability to interact with multiple systems, modulating processes like inflammation, oxidative stress, and cell survival.
Neurological and inflammatory diseases, like Amyotrophic Lateral Sclerosis (ALS), are driven by a web of interconnected biological pathways, making them difficult to treat with single-target therapies. At Canurta, we believe the future lies in a multi-target approach.
Our lead candidate, CNR-401 embodies this strategy by targeting multiple key mechanisms involved in ALS. While current treatments offer limited neuroprotection and symptom relief, Canurta’s botanical therapies aim to slow disease progression, relieve symptoms, and enhance quality of life for ALS and a broader range of neurodegenerative and inflammatory diseases.
The Latest from Canurta
